Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative, Oncology, and Protein Quality Control Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STUB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STUB1 Recombinant Protein (Full-length & Mutants) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. WT, TPR, and U-box domain constructs available. |
View STUB1 Products |
| Domain Protein | STUB1 TPR Domain (1-128aa) Chaperone binding domain for HSP70/HSP90 interaction studies. |
View STUB1 Products |
| Domain Protein | STUB1 U-Box Domain (128-303aa) E2 ubiquitin-conjugating enzyme binding domain for enzymatic assays. |
View STUB1 Products |
| Gene Delivery | STUB1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation in HEK293 or neuronal cells. |
View STUB1 Products |
| Benchmark Ab | Anti-STUB1 Recombinant Antibody Positive control for Western blot, IP, and assay standardization. |
View STUB1 Products |
| Validator | STUB1 siRNA Set For knockdown verification and specificity controls. |
View STUB1 Products |
| Related Target | HSPA1A (HSP70) Primary chaperone partner; essential for TPR-mediated substrate recruitment. |
View HSPA1A Products |
| Related Target | HSP90AA1 Critical chaperone; required for STUB1 protein-protein interaction (PPI) assays. |
View HSP90AA1 Products |
| Related Target | CRBN Standard E3 ligase for PROTAC benchmarking and cross-selectivity screening. |
View CRBN Products |
| Related Target | MAPT (Tau) Neurodegenerative substrate for validation in Alzheimer's models. |
View MAPT Products |
| Related Target | CFTR Key substrate for folding and degradation quality-control assays. |
View CFTR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (TPD) | E. coli & HEK293 expressed proteins with strict sequence verification for precise SPR/TR-FRET binding kinetics. |
| E3 Ligase Activity Reconstitution & Auto-Ubiquitination | High-purity WT and catalytically dead U-box mutant (e.g., H260Q) proteins. Sequence verified. HEK293 expressed for native folding. |
| Chaperone Interaction Mapping (TPR Domain) | Isolated TPR Domain (aa 1-128) strictly verified by mass spec for HSP70 C-terminal EEVD motif binding studies. |
| Ubiquitination Cascade Validation | U-Box Domain fragment (aa 128-303) for specific E2 enzyme (UBE2D/UBE2N) recruitment assays. |
| Substrate Recruitment & Specificity | Isolated TPR-domain and HSP70-binding mutant constructs available. >95% purity for SPR/BLI. |
| Intracellular Target Engagement | Lentivirus particles for stable overexpression in HEK293 or SH-SY5Y neuronal cell lines. |
| Lack of Reliable Controls | Catalytically dead mutants, scrambled siRNA, and benchmark antibodies included for assay standardization. |
| False Positives in Cellular Assays | Endotoxin <1 EU/µg; mass-spec identity verification; HEK293 expressed options. |
Live STUB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STUB1-targeted therapeutics is intensifying, with major players shifting focus from traditional enzyme inhibitors to bivalent modalities including PROTACs and molecular glues. As an E3 ubiquitin ligase, STUB1 (CHIP) offers a compelling alternative to CRBN and VHL, especially for CNS indications. First-generation tool compounds are entering lead optimization, while the next wave targets CNS-penetrant activators for neurodegeneration and selective inhibitors for cystic fibrosis and oncology. The protein quality control field is maturing, and next-generation therapies are expected to address drug resistance and tissue-specific delivery challenges.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Emerging biotech | Oncology (p53 stabilization) | E3 Ligase Activity Assay (Need full-length active protein with intact U-box) |
| Small Molecule Activators | Neurodegeneration Biotech / Academia | Alzheimer's, Parkinson's, SCAs | Ubiquitination Cascade (Need high-purity WT & dead-mutant STUB1) |
| PROTACs / Degraders | Preclinical Biotech, Academia | Solid Tumors, Neurodegeneration | Ternary Complex Formation (Need high-purity WT/Mutant Proteins) |
| Molecular Glues | Pharma Innovators, Undisclosed | Refractory Cancers, Inflammation | PPI Validation (Need Chaperone partners like HSP70/HSP90) |
| Peptide Disruptors | Biotech peptide engineering | Protein aggregation disorders | TPR:HSP70 Binding Assay (Need high-purity TPR domain) |
| Gene Modulation (AAV/siRNA) | Gene Therapy Pioneers | Spinocerebellar Ataxia | Stable Cell Line Construction (Need STUB1 ORF Lentivirus & siRNA) |